Archives des World-Leading Research | Page 5 of 7 | The Ottawa Hospital Foundation

Hope despite aggressive skin cancer diagnosis

Diagnosed with a stage 4 melanoma at the age of 62, Dan Collins feared for his life when he learned about the aggressive form of cancer. However, immunotherapy treatment gave him a reason to hold out hope. Dan had hope because of scientists who never gave up; who were determined to turn the tables on cancer and to create a better chance of survival, for patients like him. Hope that a cure is coming.

Discovery of a mass

Four years ago, Dan had been travelling for work, when he started noticing some pain when he’d lean his head back to rest on the plane. He recalls turning to his family doctor to get answers. An ultrasound revealed there was something inside the back of his head that looked like a cyst.

After an initial biopsy, Dan was referred to a surgeon at The Ottawa Hospital Cancer Centre. Another biopsy revealed the cyst was actually a mass. It was melanoma. “I was scared. Cancer had stripped my family of so much. I lost both of my two older brothers and my father to cancer. I feared for my life,” recalls Dan.

Unfortunately, the mass starting growing – and it was growing fast. By the end of July, just two months later, the mass went from being not visible on the back of his head, to the size of a golf ball.

His surgical oncologist, Dr. Stephanie Obaseki-Johnson, initially wanted to shrink the tumour before surgery to remove it. However, the mass was growing too quickly.

Oncologist Dr. Michael Ong of The Ottawa Hospital in a patient room. — *Dan Collins with Oncologist Dr. Michael Ong.*

Time to act

On August 11, 2015, Dan had surgery that lasted most of the day. When it was over, he had 25 staples and 38 stitches in the back of his head. As he recovered, Dan was reminded of a saying that helped him through recovery, “Never be ashamed of your scars. It just means you were stronger than whatever tried to hurt you.”

He would need that strength with the news that awaited him. Only two weeks later, the mass was back. His doctors also discovered a mass in his right lung and shadows in the lining of his belly. He had stage 4 cancer – it had metastasized. This was an aggressive cancer that left Dan thinking about the family he had already lost and what would happen to him.

The next generation of treatment

Soon, he was introduced to The Ottawa Hospital’s Dr. Michael Ong and was told about immunotherapy – the next generation of treatment, with the hope of one day eliminating traditional and sometimes harsh treatment like chemotherapy. Dr. Ong prescribed four high doses of immunotherapy. At the same time, radiation treatment began for Dan – 22 in all. His immunotherapy treatments were three weeks apart at the Cancer Centre and between each, he would have an x-ray to monitor the tumours.

“Each x-ray showed the tumours were getting smaller. That’s when the fear started shifting to hope.” – Dan Collins, patient

By December 2015, Dan finished immunotherapy treatment and the next step was to wait. “This transformational treatment was designed to train my own immune system to attack the cancer. We would have to be patient to see if my system would do just that,” says Dan.

While the shadows in Dan’s stomach lining had shrunk, the mass in his lung had not. That’s when Dr. Ong prescribed another immunotherapy drug that would require 24 treatments.

Dan learned from his oncologist that melanoma has gone from being an extremely lethal cancer, with few treatment options, to having many different effective therapies available.

“When I started as an oncologist a decade ago, melanoma was essentially untreatable. Only 25 percent would survive a year. Yet now, we can expect over three quarters of patients to be alive at one year. Many patients are cured of their metastatic cancer and come off treatment. We are now able to prevent 50 percent of high-risk melanoma from returning because of advances in immunotherapy,” says Dr. Ong.

Dan completed his last immunotherapy treatments in September 2017.

Oncologist Dr. Michael Ong posing with armed crossed at The Ottawa Hospital. — *Oncologist Dr. Michael Ong of The Ottawa Hospital.*

Today, there is no sign of cancer

When Dan thinks back to the day of his diagnosis, he remembers wondering if he was going to die. “I believe I’m here today because of research and because of those who have donated to research before me.”

He thinks back to when his older brother Rick died of cancer in 2007. “At the time he was treated, his doctor asked if he would participate in a research study. The doctor told him directly, this would not help him, but it would help somebody in the future.” Dan pauses to reflect and then continues, “I like to think, that maybe, he had a hand in helping me out today. Maybe he helped me survive. One thing I do know is that research was a game changer for me.”

The Ottawa Hospital has been a leader in bringing immunotherapy to patients. Research and life-changing treatments available at The Ottawa Hospital altered Dan’s outcome and he hopes that advancements will continue to have an impact on many more patients, not only here at home but right around the world.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Cancer, Cancer, Cancer, Cancer, Cancer, Creating Tomorrow, Patient Care

Update: In early 2023, Dr. Thébaud’s team treated the first baby in their clinical trial that aims to prevent BPD in premature infants. This is the first trial of its kind in in the world. Read Dr. Thébaud’s Q&A to learn more about his critical work and what motivates him.

Published: August 2020

Little Olivia Eberts had oxygen tubes in her nose until after her first birthday. Because she was born prematurely, her tiny lungs were underdeveloped, and she couldn’t breathe without oxygen. Ironically for Olivia, and many premature babies like her, the oxygen that saved her life also damaged her lungs, causing bronchopulmonary dysplasia (BPD), which is like starting out life with emphysema. But a clinical trial at The Ottawa Hospital led by Dr. Bernard Thébaud, which uses stem cells to heal the lungs of premature babies, may be a game changer.

An unexpected early birth

Jamie Eberts was 22 weeks pregnant with twins when she started feeling some discomfort. She arrived at the General Campus of The Ottawa Hospital and was admitted — she was going into early labour.

Thankfully, the doctors and nurses at The Ottawa Hospital were ready for any scenario Jamie, her husband Tim, and the babies faced. Each day, there were gentle conversations about how the babies were doing, the process of delivering them, and the chances of survival. Every hour counted. Then, one of the babies developed an infection and all three lives were at risk — the babies had to be delivered.

Baby in NICU — Baby Olivia in the neonatal intensive care unit (NICU).

“Our babies, Liam and Olivia, were born at 5 a.m. on January 29, 2017, at 23-and-half-week’s gestation. Liam was born first. He was small, red, and didn’t make a sound,” remembers Jamie. Olivia weighed one pound, two ounces and Liam weighed only a few ounces more than she did. Both babies required oxygen and mechanical ventilation to keep them alive. As a result, both developed BPD — the most common cause of death in premature babies.

Sadly, baby Liam passed away a few weeks after he was born while Olivia remained in the Neonatal Intensive Care Unit (NICU) at The Ottawa Hospital for nine long months.

BPD in Canada

In Canada, 1,000 babies are diagnosed with BPD every year. Often, babies with BPD develop other chronic lung diseases, such as asthma, and many require prolonged oxygen and ventilation. Additionally, they have a high incidence of hospital readmissions in the first two years of life. Babies with BPD often have problems in other organs as well, such as the brain or the eyes.

When Olivia was finally discharged, she went home with an oxygen tank. During the first year of her life, Olivia spent more time in hospital than out.

“Even now, a simple flu that put me in bed for a couple of days put her in hospital and turns into pneumonia. It’s scary,” says Jamie. The doctor told her that with Olivia’s respiratory issues, she may require hospital intervention for the rest of her life.

Lack of treatment options

“Currently there is no treatment for this disease,” says Dr. Bernard Thébaud, a neonatologist and senior scientist at The Ottawa Hospital. With that being said, he’s determined to improve the outcome for babies, like Olivia, who have BPD.

 “In the laboratory, we discovered that a particular type of stem cell can prevent BPD or regenerate newborn lungs.”
— Dr. Bernard Thébaud

Read our Q&A with Dr. Bernard Thébaud

Dr. Bernard Thebaud, neonatal intensive care unit, The Ottawa Hospital — Dr. Bernard Thebaud in the neonatal intensive care unit (NICU) at The Ottawa Hospital.

“Our research uses stem cells, isolated from the umbilical cords of healthy newborns, to prevent the lung injury or even to some degree regenerate a damaged lung in the laboratory. We foresee that these stem cells, given during a certain time during the hospital stay of these babies, could prevent the progression of the lung disease.”

Unlike traditional stem cells that can directly replace damaged cells and tissues, the stem cells that Dr. Thébaud is studying work by producing healing factors that promote regeneration and repair.

Clinical trial offers hope

Dr. Thébaud and his research team have launched a phase I clinical trial to test the feasibility and safety of the stem cell treatment in premature babies. The team is doing everything in their power to make this clinical trial a success, including consulting with healthcare providers and parents of premature babies.

One thing they’ve learned from these consultations is that many parents don’t feel like they know enough about stem cells and clinical trials to decide if they want to enroll their child in the trial. So, Dr. Thébaud and his team created an animated video to explain these concepts and help parents make an informed decision. Parents can share the video with family members if they’d like a second opinion.

Jamie was involved in these consultations and her firsthand experience provided valuable insight to the research team as they planned this project. This is just one example of how researchers at The Ottawa Hospital are partnering with patients and caregivers to improve the quality and success of their research.

Dr. Bernard Thébaud looks at a premature baby in an isolette.

Dr. Thébaud and his team held a “dress rehearsal” for the clinical trial. “The dress rehearsal lets us test and tweak our tools for approaching parents, including the video, so we know what works best once we’re ready to begin offering the experimental treatment.”

If this initial trial is successful, Dr. Thébaud and his team will launch a larger Canadian clinical trial. “This is a critical step towards providing a potential breakthrough therapy that could help premature babies in Canada and around the world,” says Dr. Thébaud.

The made-in-Ottawa clinical trial is supported by The Ottawa Hospital’s Ottawa Methods Centre and Biotherapeutics Manufacturing Centre, and the Blueprint Translational Research Group.

First trial of its kind in Canada

“Stem cell research is incredibly innovative. Here, we have a very promising, emerging therapy that could prevent lung injury but also improve brain development and eyesight,” says Janet Brintnell, Clinical Manager of the NICU who has seen dozens of premature babies with BPD.

“It’s amazing when you think of what it may be able to do for the quality of life for the child, for their family, and for our healthcare system. It could reduce length of stay, hospital admissions, and improve long-term outcomes. It could help these little ones lead healthier lives.”
— Janet Brintnell

“We are the only ones doing this kind of stem cell research in Canada, and there are only a few other teams in the world that are doing this.”
— Dr. Bernard Thébaud

Yet, three years ago when Olivia was in the NICU, this treatment wasn’t yet available. Now, Jamie and Tim are self-described “cheerleaders” of Dr. Thébaud’s research and are hopeful for what it might mean for future preemies and their families.

“I believe this is our future,” says Jamie. “When I think about what this could have done for our family, I wonder if Liam could have possibly survived. Olivia may not be facing the delays she’s experiencing today. Even to this day, if we are asked to put Olivia in the trial as an older candidate, we will.”

Jamie also adds the there was an impact from a mental health and financial perspective. “Our oldest child, Jacob, has had a very unusual first four years of his life because of how adaptable he has had to be during these difficult times. As a family, this entire experience has been very challenging financially due to a variety of therapies for Olivia and having to get used to becoming a single income family for several years in order to manage Olivia’s complicated schedule. All of this could have potentially been avoided if Dr. Thébaud’s research were available to our twins.”

A new beginning

Olivia is now a happy, active toddler who loves copying what her older brother Jacob does. Although, she still has BPD, it is increasingly manageable, and she no longer requires supplemental oxygen. While Olivia may suffer respiratory illness her entire life, one day a stem cell treatment developed here in Ottawa could mean that the next generation of babies with BPD won’t.

Listen to Pulse Podcast and learn how one day stem cells could heal the lungs of premature babies with Dr. Bernard Thébaud and what it could mean for parents like Jamie Eberts.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Biotherapeutics, Creating Tomorrow, NICU, Stem Cell

Could cancer biotherapeutics be the next revolution in cancer treatment?

From helping the body’s own immune system better detect and fight cancer, to treating cancer with genetically-enhanced immune cells, viruses and vaccines, The Ottawa Hospital is conducting cutting-edge research that could transform cancer care right here at home and around the world.

For decades, scientists have tried to stimulate the immune system to attack cancer cells. A breakthrough came through the discovery that cancer cells make key molecules that suppress immune cells and prevent them from attacking the cancer. This discovery opened the door to revolutionary immunotherapy drugs called checkpoint inhibitors, which have shown striking results in recent years.

While promising research on checkpoint inhibitors continues, the race is now on to bring an innovative new kind of immunotherapy to patients – one that uses living cells, viruses and genes to fight cancer.

The Ottawa Hospital is a world leader in developing these innovative therapies, called cancer biotherapeutics.

“Our immune system is constantly trying to recognize and kill cancer cells, but the cancer cells are always trying to hide from it.”
— Dr. John Bell

Helping the body recognize and destroy cancer

CAR T-cell therapy is an emerging biotherapeutic treatment that harnesses the power of a patient’s own immune cells, known as T-cells, to treat their cancer. T-cells play a critical role in the immune system by killing abnormal cells, such as cells infected by germs or cancer cells. In some cancers, like acute lymphoblastic leukemia (ALL), cancerous cells become invisible to the T-cells that are meant to kill them. In CAR-T therapy the T-cells are collected and reprogrammed in the lab to recognize and destroy the cancerous cells.

“This type of immunotherapy research is groundbreaking,” said Dr. Natasha Kekre, a hematologist and associate scientist at The Ottawa Hospital, “but it is important to remember that CAR-T therapy is still very new and there can be serious side effects. We need more research to learn about this therapy and make it work for even more people and more kinds of cancer.”

The Ottawa Hospital is one of the first hospitals in Canada to participate in internationally-led CAR-T trials, and as one of Canada’s top research and treatment centres, the hospital is ideally positioned to play a lead role in bringing an innovative CAR-T research program to Canada, and to Canadian patients.

“Our goal is to build Canadian expertise and capacity for innovation in the promising CAR-T field through both laboratory research and clinical trials,” said Dr. Kekre, who is working with a team across the country. “This could lead to better CAR-T therapies that work for more kinds of cancer, as well as innovative approaches for providing CAR-T therapy in the Canadian system.”

Infecting cancer cells with viruses

Another promising biotherapeutic treatment uses oncolytic viruses that selectively infect and kill cancer cells. “Our immune system is constantly trying to recognize and kill cancer cells, but the cancer cells are always trying to hide from it,” explained Dr. John Bell, senior scientist at The Ottawa Hospital. “When you infect a cancer cell with a virus, it raises a big red flag, which helps the immune system recognize and attack the cancer.”

Recent laboratory research from Dr. Bell’s team suggests that a combination of two immunotherapies, oncolytic viruses and checkpoint inhibitors, could be much more successful in treating breast cancer and possibly other cancers.

“We found that when you add a checkpoint inhibitor after the virus, this releases all the alarms and the immune system sends in the full army against the cancer,” said Dr. Bell.

Though these methods have shown promising results, more research and clinical trials are needed.

Cancer-fighting vaccine

In addition to these techniques The Ottawa Hospital’s Dr. Rebecca Auer has found that a cell vaccine, developed in the lab using an individual’s cancer cells combined with a cancer-fighting virus, could be effective in battling cancer. Once injected, this vaccine uses a triple-threat to attack the cancer.

Doctor speaking with a patient in her office at a hospital — Dr. Rebecca Auer, The Ottawa Hospital

First, the virus only infects and kills cancer cells, leaving healthy cells unscathed. Second, the virus produces a protein called interleukin-12, which boosts the immune system’s natural ability to fight the tumour. Third, as a result, the vaccine trains the immune system to recognize and fight off the same kind of tumour if it ever comes back.

Dr. Auer and her colleagues are developing the processes required to manufacture this personalized cell vaccine and plan to initiate a “first in human” clinical trial in 2020.

Lifesaving therapies: from idea to bedside

Today, cancer care is changing at an unprecedented pace. Many patients who, only a few years ago, had few to no treatment options are now being offered hope with treatments that are more targeted and personalized. We are seeing approvals for new cancer drugs grow at an almost exponential rate, while world-class research and clinical trials are being integrated into cutting-edge cancer care.

Over the next 15 years, Canadians will see a 40 percent increase in cancer diagnoses with almost one in two developing cancer in their lifetime. Our ability to translate research into patient therapies coupled with one of the best-equipped cancer centres in the country means we are well-positioned to face this challenge head-on.

Go inside the Biotherapeutics Manufacturing Centre at The Ottawa Hospital.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Biotherapeutics, Immunotherapy

OCTOBER 26, 2019 OTTAWA, ON – It was a sold-out night at The Ottawa Hospital Gala, presented by First Avenue Investment Counsel, which recognized three innovative researchers. The elegant ballroom of the Westin Hotel was transformed with exquisite décor and a delectable four-course meal, enjoyed by more than 700 guests. It also marked the final gala with Dr. Jack Kitts as President and CEO of The Ottawa Hospital, who will retire in 2020. Guests paid tribute to Dr. Kitts with a standing ovation for his dedication to providing compassionate and world-class care to the Ottawa community through his leadership since 2002.

The Ottawa Hospital Gala celebrated the transformational work of three researchers dedicated to improving care. Congratulations to this year’s three award winners:

Faizan Khan, recipient of the Worton Researcher in Training Award, recognized for his outstanding work on vein blood clots, including a recent British Medical Journal study establishing long-term risks and consequences of clot recurrence.

Dr. Marjorie Brand, recipient of the Chrétien Researcher of the Year Award, recognized for her groundbreaking discovery of how a blood stem cell decides whether to become a red blood cell or a platelet-forming cell.

Dr. Paul Albert, recipient of the Grimes Research Career Achievement Award, recognized for his leadership in Neuroscience, as well as his innovative work on what causes depression and how to treat it.

The Ottawa Hospital is recognized for its world-leading research that attracts internationally recognized scientists and clinicians from around the world. Tim Kluke, President and CEO of The Ottawa Hospital Foundation, emphasized that it’s corporate and individual philanthropic gifts, which make that a reality. “We are privileged to have the support of a generous community which is helping this city advance research to find new hope for patients now and in the future.”

First Avenue Investment Counsel returned as the presenting sponsor of The Ottawa Hospital Gala this year. Kash Pashootan, CEO and Chief Investment Officer at First Avenue Investment Counsel, said it’s a partnership that aligns perfectly. “Innovative research is a necessary investment in the future of health care in our community and we’re proud to fulfill our duty to The Ottawa Hospital. At First Avenue Investment Counsel, we advise families on all aspects of their financial picture including managing their assets to ensure their secure future for them and future generations. Together, we’re laying the building blocks for the future.”

About The Ottawa Hospital: 

The Ottawa Hospital is one of Canada’s largest learning and research hospitals, with more than 1,200 beds, 12,000 staff members and an annual budget of about approximately $1.3 billion.

The focus on learning and research helps to develop new and innovative ways to treat patients and improve care. As a multi-campus hospital affiliated with the University of Ottawa, specialized care is delivered to the eastern Ontario region and the techniques and research discoveries are adopted around the world. The hospital engages the community at all levels to support our vision for better patient care.

From the compassion of our people to the relentless pursuit of new discoveries, The Ottawa Hospital never stops seeking solutions to the most complex patient-centred care. For more information about The Ottawa Hospital, visit ohfoundation.ca.

Local activist donor pledges $500,000 to take on cancer

*Gavin Murphy takes pride in describing himself an activist donor.*

Gavin Murphy is unwavering when it comes to his desire to maintain a world-class health care system in our city. He’s unwilling to settle for anything less and he doesn’t think anyone in our community should either. Gavin believes each resident needs to play an active role in giving back, and that’s why this self-described “activist” donor is sharing his story – a story he hopes will lead to a cure for cancer.

This New Edinburgh resident has committed $500,000 to support the Radiation Medicine Program at The Ottawa Hospital – it’s what he wants his lasting legacy to be.

While the Ottawa lawyer isn’t looking for public recognition, he’s not shy about sharing the news of his gift as he hopes it will inspire others to do the same. “Scarce government resources requires those in a position to give significant gifts to step forward and support The Ottawa Hospital.” Gavin adds, “By giving serious thought to my philanthropy, I am hoping to help improve discovery and care for our families, friends, and neighbours.”

Gavin’s interest in cutting-edge research is what enticed him to make this tremendous gift to Radiation Medicine Program with the hope that findings will one day be published. He’s excited about the opportunities which lie ahead and the advancements that will be made.

“I want to give this money while I’m still alive. It’s great that people leave money in their estates, I think that’s wonderful but I want to see the fruits of my labour, in my lifetime.” – Gavin Murphy

It’s the fruits of his labour, which will leave his fingerprints on advancements in cancer care to help others in the future. For Gavin, that’s truly exciting. “I like the idea of funding new, innovative technology. It will leave a lasting legacy and this gift is providing the building blocks for future research in this field.”

Donor support is vital to providing doctors and researchers with state-of-the-art tools. It’s also what allows The Ottawa Hospital to be a trailblazer when it comes to transformational advancements. Dr. Miller MacPherson, the Head of Medical Physics at The Ottawa Hospital says, “It’s the generosity of donors like Gavin which allows The Ottawa Hospital to be innovative with new technologies. This support will provide insight for new discoveries and will have an impact on care through research and technology advancements in the field of cancer research.”
Dr. Jason Pantarotto, Head of Radiation Oncology at The Ottawa Hospital, echoes that sentiment, noting that donations to the Radiation Medicine Program are particularly precious. “Despite radiotherapy being a key treatment for nearly 5,000 cancer patients each year in Ottawa, the amount of research dollars available to improve the science is pretty sparse. We are extremely grateful to donors, such as Gavin, who see the benefits of investing in the team and equipment that exists here at The Ottawa Hospital.”

For Gavin, his ultimate goal is to help find a cure for cancer.

“This gift will provide a foundation to greater understanding of cancer and I hope it will help obliterate cancer sometime down the road.”- Gavin Murphy

The reality is The Ottawa Hospital will touch each person in our community in some way. For Gavin, that’s a good reason for not only himself but also for others to step forward. “If people want to be well looked after in a world-class system, we have to ensure a world-class system is maintained.”

The way Gavin sees it, we’ll all need The Ottawa Hospital at some point, and there’s a way for each person in our community to support it. “You need people who are in the position to give, and those who can give smaller amounts, in greater numbers to support the hospital equally.”

Download Pulse podcast to hear Gavin’s message to the community about why future support is critically important.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Donors, Innovation and Technology, Technology

SEPTEMBER 25, 2019, OTTAWA, ON – September resulted in $2.21 million donated to The Ottawa Hospital as a direct result of community support – solidifying our city’s dedication to ensuring world-class care and research in eastern Ontario. Events including THE RIDE, powered by Mattamy Homes, the President’s Breakfast, golf tournaments, and community-inspired events, all contributed to this excellent example of dedication local residents have to The Ottawa Hospital.

The funds will directly support patient care and research at The Ottawa Hospital. Tim Kluke, President and CEO of The Ottawa Hospital Foundation, said this is a perfect example of a community rallying to ensure doctors, researchers and nurses have the right tools to care for their patients. “Philanthropy takes many forms, and each of these special events embodies the important role The Ottawa Hospital plays in our city. We are grateful for all of the support and we never take it for granted,” said Kluke.

In many cases, community leaders stepped forward to support The Ottawa Hospital and called on their friends and colleagues to do the same. This was the case for Cyril Leeder and Janet McKeage who co-chaired the annual President’s Breakfast held earlier this month.

“Beyond the right tools and equipment, research is fundamental to the advancements in care we are seeing. It’s research which is allowing The Ottawa Hospital to be one of the best health-care centres in the country and it is the generosity of our community which makes that possible,” said Leeder.

McKeage echoed that sentiment, “Together, we have the capability to help push the boundaries when it comes to health care in our city.”

It is community support, which provides critical funds to help purchase equipment not funded by our tax dollars and helps fund the work of a researcher who has dedicated his or her life to finding a cure.

About The Ottawa Hospital:

The Ottawa Hospital is one of Canada’s largest learning and research hospitals, with more than 1,200 beds, 12,000 staff members and an annual budget of about approximately $1.3 billion.

The focus on learning and research helps to develop new and innovative ways to treat patients and improve care. As a multi-campus hospital affiliated with the University of Ottawa, specialized care is delivered to the eastern Ontario region and the techniques and research discoveries are adopted around the world. The hospital engages the community at all levels to support our vision for better patient care.

From the compassion of our people to the relentless pursuit of new discoveries, The Ottawa Hospital never stops seeking solutions to the most complex patient-centred care. For more information about The Ottawa Hospital, visit ohfoundation.ca.

30 years after treatment, leukemia survivor forever grateful

The importance of cancer research is not lost on Robert Noseworthy. He’s reminded of it every time he looks in the mirror.

Robert is a cancer survivor and not a day goes by that he doesn’t appreciate each moment he’s had to share with his two children, who are now adults.

On October 21, 1988, Robert was diagnosed with acute lymphoblastic leukemia—a childhood leukemia. He was living in Montreal at the time with his young family, including Julianne who was 18 months old and his infant son, David.

A grim prognosis

“I was given a 13% chance of survival with 6 months to live. My doctor said it was very unusual for a 30-year-old to have a childhood leukemia,” says Robert.

And so, the cancer journey began for this father of two. It would include numerous rounds of chemotherapy and radiation treatments, which put him into remission, but the journey didn’t end there. “In March 1989, I received a bone marrow transplant from my sister, who was a six-on-six match.”

Thanks to that match, Robert beat the odds. He gives full credit to cancer research as the reason he is alive today. It’s what has driven Robert and his family to become dedicated supporters of cancer research at The Ottawa Hospital. “That is my why. I do my small part and to raise funds for cancer research,” he says.

*Robert Noseworthy with his daughter Julianne after they cycled 109 kms during THE RIDE on September 8, 2019.*

Time to give back

Giving back has been important to Robert. Each year, his family comes together to cycle and raise funds through THE RIDE, a cycling fundraiser. It’s also been important to him to instill that in his children as they grew up. “I received all this help but now it’s time to give back.”

For Julianne, giving back as a family to The Ottawa Hospital and advancing research has become just as important to her.

“If it wasn’t for cancer research and everything my dad had been through, we wouldn’t be the family that we are today,” says Julianne.

Glancing over at her father, with a smile, Julianne says, “My why is you.”

The way Robert sees it; he is alive because of the investment of others who came before him and he wants to be that hope for someone else battle cancer. “60 years ago someone invested in cancer research. 30 later, I was the beneficiary of that generosity and that’s why I’m here today.”

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Cancer, Donors

A melanoma diagnosis

The Ottawa Hospital, The Ottawa Hospital Foundation, Ian McDonell — *Ian McDonell received immunotherapy in 2017, which erased any trace of his melanoma.*

Several years ago, Ian McDonell, a Staff Sergeant with the Ottawa Police and father of three had just lost his father to cancer and his brother was dying of melanoma. Ian’s wife insisted he see his physician to check out a mole on his back. It turned out to be an ulcerated nodular malignant melanoma – an aggressive form of skin cancer.

Ian had surgery to remove it along with a lymph node from his left groin. Several weeks later, he had a lymph node removed from his armpit. Following these surgeries, he had no signs of cancer, but due to his family’s history, Ian was at high risk for relapse.

Sobering news

Ian was feeling well, but during a standard monitoring visit in June 2017, his CT and MRI scans showed sobering news. He had half a dozen tumours in his groin and abdomen, and three more tumours metastasized to his brain. Ian’s cancer was stage 4.

Given the severity of the findings, Dr. Michel Ong at The Ottawa Hospital suggested an aggressive approach – a recently approved immunotherapy treatment.

Unmasking cancer

Scientists have tried for decades to stimulate the immune system to attack cancer cells. But the game changer was the discovery that cancer cells make key molecules, called immune checkpoint proteins, that suppress immune cells and prevent them from attacking the cancer. These immune checkpoint proteins cloak the cancer from the immune system. New drugs called immune checkpoint inhibitors remove this cloak and allow immune cells called T-cells to naturally attack and destroy the cancer.

“The idea of chemotherapy is to kill off cancer directly,” said Dr. Ong. “There are potential side effects, because chemotherapy tries to poison the cancer.

“Immunotherapy does not directly affect the cancer itself. Instead, immunotherapy unmasks the cancer to your immune system by flipping some switches on T-cells, and the body’s own immune system does the rest.” – Dr. Michael Ong

Ian McDonell with his wife Michelle (left), and their daughters Kendra, Macy, and Ainsley, hiking in the Adirondack Mountains in 2019. — *Ian McDonell with his wife Michelle (left), and their daughters, hiking in the Adirondack Mountains in 2019.*

CyberKnife treatment

Ian started on a combination of two immunotherapies given intravenously in the chemotherapy unit at The Ottawa Hospital’s Cancer Centre. He also underwent CyberKnife radiotherapy treatment where high doses of radiation were directed at his brain tumours. He bravely continued with the second round of immunotherapy, but was so sick, he had to be taken off the treatment and started on steroid medications to slow down the immune system. Ian felt better, but his immunotherapy was on hold.

Shrinking tumours

When Ian began to develop weakness in his face, he worried his cancer was getting worse. It wasn’t. Scans showed one tumour had shrunk from 25 to 10 mm, and another had shrunk from eight to four mm.

Dr. Ong recommended trying a single immunotherapy rather than two, and while the treatment made Ian very sick, it did the trick.

Two months later, the results of a PET scan, MRI, and a CT scan showed that he was tumour-free. All trace of his cancer was gone.

*Oncologist Dr. Michael Ong said recent immunotherapies are hugely successful for treating melanoma.*

Advances in immunotherapy

When Dr. Ong first met Ian in 2013, options for immunotherapy or targeted chemotherapy weren’t available. Thanks to incredible advances in immunotherapy, there is now hope.

“In the last few years, we’ve gone from having very poor options to having many effective options for melanoma. That’s because cancer therapy continues to develop at a very rapid pace,” said Dr. Ong. “We, at The Ottawa Hospital, are constantly participating in practice-changing clinical trials. The standard of care is constantly changing, as it should. We are continually trying to push the limits of cancer treatment.”

The Ottawa Hospital is a leader in cancer immunotherapy research, both in terms of developing new therapies and in offering experimental treatments to patients. Currently, there are approximately 70 active cancer immunotherapy clinical trials being conducted at the hospital involving nearly 700 patients. The hospital also hosts a national network for immunotherapy research and has developed a number of unique immunotherapies made directly of cells and viruses.

Hope for the future

Because of successful immunotherapy treatments, patients like Ian are now planning a future of living cancer-free.

“When the provincial exams for police services came up, I said, ‘I’m gonna write it, because I’ve got a bit of hope now.’” said Ian.

More importantly, in addition to his career plans, immunotherapy has allowed Ian to plan for the future with his family and a chance to watch his daughters grow up.

Hear more about oncologist Dr. Michael Ong’s work with immunotherapy.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Clinical Trials, Immunotherapy, Immunotherapy, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research

Annette ringing the bell of hope following her final cancer treatment.

In July 2016, Annette Gibbons had a routine mammogram. She didn’t expect that day would become a pivotal moment in her life and lead to a breast cancer diagnosis. This unexpected news sent her on a journey of treatment, surgery, and uncertainty that required she place her complete trust in her medical team at The Ottawa Hospital for both her physical and emotional well-being.

Following the mammogram, Annette was told that she had dense tissue, which made it difficult to read the results. She wasn’t worried at all when she received a call to schedule another mammogram and ultrasound. But that all changed when her radiologist, Dr. Susan Peddle, gently told her that she thought it was cancer.

Annette, visibly emotional, recalls that fateful day. “Just like that, my life changed and I began my journey.”

The challenges of chemotherapy set in

Annette began chemotherapy treatment under the watchful eye of medical oncologist and scientist Dr. Mark Clemons. “He specializes in the type of cancer I had and is very active in clinical trials and research on leading-edge treatments and practices,” said Annette.

During these early days, she focused solely on getting through the wear and tear of chemotherapy. She recalls that “it’s not anything you can truly prepare for, or understand, until you’re the patient…There was the depressing hair loss, the constant nausea, the searing bone pain and the mind-numbing fatigue. Despite all that, I still tried to keep my spirits up with exercise, a support group, and lots of old movies.”

Research making a difference

During her treatment, Annette participated in several clinical trials led by Dr. Clemons through his innovative REthinking Clinical Trials (REaCT) program. This program engages patients and their loved ones in research every step of the way, from generating ideas to setting priorities to designing studies and sharing results.

One of the studies that Annette participated in has now produced important results that are helping breast cancer patients not only in Ottawa, but around the world.

Trusting her medical team

She also put her complete trust in her medical team and was determined to stay positive. “I knew the stats for survivability were fairly good and I looked forward to resuming my ‘normal life’.”

Little did she know that the next steps – mastectomy and radiation – would be tougher than chemotherapy. The surgery itself and healing had gone well. She credits her amazing surgeon, Dr. Erin Cordeiro, for her compassion and skill.

“She held my hand as I lay in the operating room preparing for the operation to begin.” – Annette Gibbons

“In the end,” Annette says with a little smile on her face, “she gave me, dare I say, the nicest, straightest surgery scar I have ever seen on anyone.”

Sobering news

Annette wouldn’t have the full picture of her cancer prognosis until pathology results came back on her tumour. Several weeks later she received alarming results from Dr. Cordeiro. It was devastating news. “She told me that my tumour was much bigger than first thought. They had found cancer in many of the lymph nodes they removed. I was not expecting that, it was a huge blow.”

As she tried to absorb this news, she sat down with Dr. Clemons a few days later and was dealt another blow. “He gave it to me straight: because of the tumour size and number of lymph nodes affected, my risk of recurrence was high.”

Compassionate care during a dark time

That’s when Annette’s world came crumbling down. She recalls spiralling down into a dark place. “It was very hard to crawl out of this place. But my medical team saw the signs and knew how to help me. My dedicated radiation oncologist, Dr. Jean-Michel Caudrelier, spotted my despair and referred me to the psychosocial oncology program. With the amazing help of Dr. Mamta Gautam, I walked through my deepest fears and came out the other side.”

Annette completed her radiation treatment and then slowly reclaimed her life. But as all cancer patients know, the fear of recurrence can be a constant companion. “I don’t know if that will ever change. But I decided to make it my friend who reminds me to think, not about dying, but about the importance of living while I am alive,” said Annette.

She’s grateful to know the best medical professionals were right here in her hometown when she was diagnosed. As a self-proclaimed “frequent flyer at the hospital”, Annette is proud to say she’s reclaimed her life — including her return to work. “I am myself again, and life is strangely somehow better than it was before.”

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Clinical Trials, Clinical Trials

SEPTEMBER 8, 2019, OTTAWA, ON – 900 cyclists and volunteers came together Sunday and raised $1.07 million to support leading-edge research at The Ottawa Hospital. In ten years, THE RIDE, powered by Mattamy Homes, surpassed the $14 million mark.

Tim Kluke, President and CEO of The Ottawa Hospital Foundation, said the research advancements we’ve seen in the last ten years have been remarkable. “When you look at immunotherapy treatments and CAR-T cell therapy for cancer treatments to stem cell treatments for MS patients, support for research at The Ottawa Hospital has been truly transformational. The dedication we’ve seen from so many riders and volunteers over the past 10 years has been an incredible way to bring our community together.”

“The dedication we’ve seen from so many riders and volunteers over the past 10 years has been an incredible way to bring our community together.”
Tim Kluke, President and CEO of The Ottawa Hospital Foundation

When it comes to inspiring our community to give back to The Ottawa Hospital, Mattamy Homes has been a true leader. Kevin O’Shea is Mattamy Homes Division President, “We not only take great pride being the title sponsor of THE RIDE, but we also participate as a team. It’s a positive way to promote health and wellness in our workplace, as well as, support our leading health care centre in eastern Ontario.”

Making THE RIDE come to life over ten years ago had a great deal to do with Robert Merkley, founder of Merkley Supply Ltd. The team captain of The Brick Peddlers, Merkley had a vision of bringing a phenomenal cycling fundraiser to Ottawa and he, along with Claude DesRosiers and Roger Greenberg, helped make it a reality. “I remember thinking to myself, if I was spearheading this new fundraiser for The Ottawa Hospital, I had better bring together a good, strong team. That’s how The Brick Peddlers came to life. I’m proud to say it’s the largest, most successful and most enthusiastic RIDE team.”

In addition to the 50KM closed route and the 109KM open road route, the 10th edition of THE RIDE also saw the inaugural Alinker one kilometre loop. Dozens of participants joined THE RIDE using the Alinker, a relatively new walk assist bike. These bikes give people with mobility challenges a chance to be a part of this vital fundraiser for research at The Ottawa Hospital – research which could potentially help them one day.

The Ottawa Hospital is one of Canada’s largest learning and research hospitals, with more than 1,200 beds, 12,000 staff members and an annual budget of about approximately $1.3 billion.

Our focus on learning and research helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital affiliated with the University of Ottawa, we deliver specialized care to the eastern Ontario region and our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care.

From the compassion of our people to the relentless pursuit of new discoveries, The Ottawa Hospital never stops seeking solutions to the most complex health-care challenges. For more information about The Ottawa Hospital, visit ohfoundation.ca.

Hope despite aggressive skin cancer diagnosis

Hope despite aggressive skin cancer diagnosis

Discovery of a mass

Time to act

The next generation of treatment

Today, there is no sign of cancer

An unexpected early birth

BPD in Canada

Lack of treatment options

Clinical trial offers hope

First trial of its kind in Canada

A new beginning

Could cancer biotherapeutics be the next revolution in cancer treatment?

Helping the body recognize and destroy cancer

Infecting cancer cells with viruses

Cancer-fighting vaccine

Lifesaving therapies: from idea to bedside

Local activist donor pledges $500,000 to take on cancer

30 years after treatment, leukemia survivor forever grateful

A grim prognosis

Time to give back

A melanoma diagnosis

CyberKnife treatment

Shrinking tumours

Advances in immunotherapy

Hope for the future

The challenges of chemotherapy set in

Research making a difference

Trusting her medical team

Sobering news

Compassionate care during a dark time

More News